
Decision of the Athletics Integrity Unit in the Case of Ms Belinda Chemutai

Introduction

1. World Athletics has established the Athletics Integrity Unit ("**AIU**") whose role is to protect the integrity of the sport of Athletics, including fulfilling World Athletics' obligations as a Signatory to the World Anti-Doping Code (the "**Code**"). World Athletics has delegated implementation of the World Athletics Anti-Doping Rules ("**ADR**") to the AIU, including but not limited to the following activities in relation to International-Level Athletes: Testing, Investigations, Results Management, Hearings, Sanctions and Appeals.
2. Ms Belinda Chemutai ("the **Athlete**") is a 24-year-old road runner from Uganda¹.
3. This decision is issued by the AIU pursuant to Rule 8.5.6 ADR, which provides as follows:

"8.5.6 In the event that the Athlete or other Person either (i) admits the violation and accepts the proposed Consequences or (ii) is deemed to have admitted the violation and accepted the Consequences as per Rule 8.5.2(f), the Integrity Unit will promptly:

- (a) issue a decision confirming the commission of the violation(s) and the imposition of the specified Consequences (including, if applicable, a justification for why the maximum potential sanction was not imposed);*
- (b) Publicly Report that decision in accordance with Rule 14;*
- (c) send a copy of the decision to the Athlete or other Person and to any other party that has a right, further to Rule 13, to appeal the decision (and any such party may, within 15 days of receipt, request a copy of the full case file pertaining to the decision)."*

The Athlete's Commission of Anti-Doping Rule Violations

4. Rule 2 ADR sets out that the following shall constitute an Anti-Doping Rule Violation:

"2.1 Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete's Sample

¹ <https://worldathletics.org/athletes/uganda/belinda-chemutai-14758385>

[...]

2.2 Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method

5. On 1 October 2023, the Athlete provided a urine Sample In-Competition at the World Athletics Road Running Championships in Riga, Latvia, which was given code 7117466 and was divided into bottle A and B (respectively the “**A Sample**” and the “**B Sample**”) in accordance with the International Standard for Testing and Investigations (“**ISTI**”).
6. On 26 October 2023, following initial analysis conducted on the A Sample, the results were reported as negative for the presence of Prohibited Substances.
7. However, on 13 March 2025, the AIU informed the Athlete that it had decided that the B Sample would be split for additional analysis to be conducted and gave her the opportunity to attend and/or be represented at the opening and splitting of the B Sample in accordance with Article 5.3.3.2 of the International Standard for Laboratories (“**ISL**”).
8. On 15 March 2025, the Athlete responded to the AIU as follows: “*I agree my sample splitting to be carried on in my absence.*”
9. The B sample splitting and resealing process took place on 26 March 2025 in accordance with Articles 5.3.3.2 of the ISL. The B sample was split into a B1 Sample and a B2 sample in the presence of an independent witness. The B1 Sample was analysed, and the B2 Sample was resealed and stored.
10. On 10 April 2025, the World Anti-Doping Agency (“**WADA**”) accredited laboratory in Paris, France (the “**Laboratory**”) reported an Adverse Analytical Finding in the B1 Sample for the presence of Testosterone and its Metabolites 5 α -androstane-3 α ,17 diol (“**5 α Adiol**”) and 5 β -androstane-3 α ,17 diol (“**5 β Adiol**”)² consistent with exogenous origin (the “**Adverse Analytical Finding**”).
11. The AIU reviewed the Adverse Analytical Finding in accordance with Article 5 of the International Standard for Results Management (“**ISRM**”) and determined that:
 - 11.1. the Athlete did not have a Therapeutic Use Exemption (“**TUE**”) that had been granted (or that would be granted) for the exogenous Testosterone or its Metabolites found in the Sample; and
 - 11.2. there was no apparent departure from the ISTI or from the ISL that could reasonably have caused the Adverse Analytical Finding.

² 5 α Adiol and 5 β Adiol are metabolites of Testosterone or Testosterone precursors.

12. Therefore, on 11 April 2025, the AIU notified the Athlete of the Adverse Analytical Finding in accordance with Article 5.1.2.1 of the ISRM, including that the Adverse Analytical Finding may result in Anti-Doping Rule Violations pursuant to Rule 2.1 ADR and/or Rule 2.2 ADR and of the imposition of an immediate Provisional Suspension.
13. The Athlete was also informed of her rights, inter alia, to request the B Sample analysis, to request copies of the laboratory documentation supporting the Adverse Analytical Finding and to admit the Anti-Doping Rule Violations and potentially benefit from a one-year reduction in the period of Ineligibility pursuant to Rule 10.8.1 ADR.
14. The Athlete provided an immediate explanation for the Adverse Analytical Finding in an interview with AIU representatives on 11 April 2025 and admitted to Anti-Doping Rule Violations.
15. On 29 April 2025, the AIU received an Admission of Anti-Doping Rule Violations and Acceptance of Consequences Form signed by the Athlete confirming the admissions made in interview on 11 April 2025.

Consequences

16. Rule 10.2 ADR specifies that the period of Ineligibility for an Anti-Doping Rule Violation under Rule 2.1 or Rule 2.2 shall be as follows:
 - “10.2.1 Save where Rule 10.2.4 applies, the period of Ineligibility will be four years where:
 - (a) The anti-doping rule violation does not involve a Specified Substance or a Specified Method, unless the Athlete or other Person can establish that the anti-doping rule violation was not intentional.
 - (b) The anti-doping rule violation involves a Specified Substance or a Specified Method and the Integrity Unit can establish that the anti-doping rule violation was intentional.”*
17. Testosterone (when administered exogenously) is a Prohibited Substance under the WADA 2023 Prohibited List under the category S1.1 Anabolic Androgenic Steroids (“AAS”). It is a Non-Specified Substance prohibited at all times.
18. The period of Ineligibility to be imposed is therefore a period of four (4) years, unless the Athlete demonstrates that the Anti-Doping Rule Violations were not intentional.
19. The Athlete has not demonstrated that the Anti-Doping Rule Violations were not intentional. Therefore, the mandatory period of Ineligibility is a period of Ineligibility of four (4) years.
20. However, Rule 10.8.1 ADR provides that an athlete potentially subject to an asserted period of Ineligibility of four (4) years may benefit from a one (1)-year reduction in the period of Ineligibility based on an early admission and acceptance of sanction:

“10.8.1 One year reduction for certain anti-doping rule violations based on early admission and acceptance of sanction.

Where the Integrity Unit notifies an Athlete or other Person of an anti-doping rule violation charge that carries an asserted period of Ineligibility of four (4) or more years (including any period of Ineligibility asserted under Rule 10.4), if the Athlete or other Person admits the violation and accepts the asserted period of Ineligibility no later than 20 days after receiving the Notice of Charge, the Athlete or other Person may receive a one (1) year reduction in the period of Ineligibility asserted by the Integrity Unit. Where the Athlete or other Person receives the one (1) year reduction in the asserted period of Ineligibility under this Rule 10.8.1, no further reduction in the asserted period of Ineligibility will be allowed under any other Rule.”

21. On 11 April 2025, the Athlete was notified of the Adverse Analytical Finding and that this may result in Anti-Doping Rule Violations under Rule 2.1 ADR and/or Rule 2.2 ADR and a period of Ineligibility of four (4) years.³
22. On 29 April 2025, the Athlete returned a signed Admission of Anti-Doping Rule Violations and Acceptance of Consequences Form confirming that she admitted the Anti-Doping Rule Violations and accepted the asserted period of Ineligibility.
23. The Athlete shall therefore receive a one (1) year reduction in the asserted period of Ineligibility pursuant to Rule 10.8.1 ADR based on an early admission and acceptance of sanction.
24. On the basis that the Athlete has admitted the Anti-Doping Rule Violations under Rule 2.1 ADR and Rule 2.2 ADR, in accordance with Rule 10.2.1 ADR and the application of Rule 10.8.1 ADR, the AIU confirms by this decision the following Consequences for a first Anti-Doping Rule Violation:
 - 24.1. a period of Ineligibility of three (3) years commencing on 11 April 2025 (the date of Provisional Suspension); and
 - 24.2. disqualification of the Athlete’s results on and since 1 October 2023, with all resulting Consequences, including the forfeiture of any titles, awards, medals, points, prizes and appearance money.
25. The Athlete has accepted the above Consequences for her Anti-Doping Rule Violations and has expressly waived her right to have those Consequences determined by the Disciplinary Tribunal at a hearing.

³ This Notice of Allegation of Anti-Doping Rule Violations was issued to the Athlete in accordance with Article 5.1.2 of the ISRM, prior to a Notice of Charge issued in accordance with Article 7 of the ISRM. Considering the Athlete’s signed admission and acceptance of Consequences on 29 April 2025, no Notice of Charge was ever issued.

Publication

26. In accordance with Rule 8.5.6(b) ADR, the AIU shall publicly report this decision on the AIU's website.

Rights of Appeal

27. This decision constitutes the final decision of the AIU pursuant to Rule 8.5.6 ADR.
28. Further to Rule 13.2.3 ADR, WADA and the Uganda Olympic Committee ("**UGA-NADO**") have a right of appeal against this decision to the Court of Arbitration for Sport in Lausanne, Switzerland, in accordance with the procedure set out at Rule 13.6.1 ADR.
29. If an appeal is filed against this decision by WADA, or UGA-NADO, the Athlete will be entitled to exercise her right of cross-appeal in accordance with Rule 13.2.4 ADR.

Monaco, 30 April 2025